In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSN – Research Report), with a price target of $7.00. The company’s shares opened today at $1.90.
Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., PainReform, and Virpax Pharmaceuticals. According to TipRanks, Rahman has an average return of 7.5% and a 40.46% success rate on recommended stocks.
Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
NRSN market cap is currently $22.87M and has a P/E ratio of -1.55.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Read More on NRSN:
